Match tier
Listed
Presence
Formerly Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
Biography and Research Information
OverviewAI-generated summary
Sunil Sharma's research focuses on the design, synthesis, and application of novel chemical compounds, particularly in the areas of drug delivery and molecular targeting. His work investigates the structure-activity relationships of various molecular entities, including coumarins and pyrrolobenzodiazepinone derivatives, to understand their impact on biological processes such as inflammation and cell survival.
Sharma has explored carbohydrate-based amphiphiles for applications in pathogen inhibition and drug delivery, examining their self-assembly properties. He also investigates the use of guar gum as a base for drug delivery systems, considering different administrative routes. His research encompasses the synthesis of compounds with specific anti-inflammatory properties, aiming for selective targeting of enzymes like COX-2. Furthermore, his publication record indicates work on conjugated polymers for advanced electronic applications and studies involving animal models for infectious diseases, contributing to a broad research scope.
Metrics
- h-index: 37
- Publications: 385
- Citations: 4,990
Selected Publications
-
A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer (2026)
-
Unraveling the chemistry, pharmacological activities, and medicinal utilization of phloroglucinol: A comprehensive review (2025)
-
2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors (2025)
-
Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+) (2025)
-
Tuning magneto-dielectric properties of Bi-doped U-type hexaferrites via Maxwell-Wagner polarization engineering (2025)
-
Modulation of Nrf-2/HO-1/HIF-1α/TFAM pathways by Arbutin in rat model of cerebral ischemic stroke (2025)
-
Neuroprotective Role of Eupalitin in Streptozotocin-Induced Diabetic Rats: In Silico and In Vivo Studies (2025)
-
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer (2025)
-
A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer (2025)
-
Performance analysis of Indian private sector banks: insights from CAMELS and statistical technique (2025)
-
Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures (2025)
-
Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors. (2025)
-
Efficient synthesis of coumarin based triazole linked O-glycoconjugates as new bio-active glycohybrids (2025)
-
Retracted: Improved Detection Rate of Breast Cancer Using 3D Magnetic Resonance Imaging (2024)
-
Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update. (2024)
Collaboration Network
Top Collaborators
Krishna
Rensselaer Polytechnic Institute (US)
6 shared publications
- Self-assembly of carbohydrate-based small amphiphiles and their applications in pathogen inhibition and drug delivery: a review
- Newer Non‐ionic A<sub>2</sub>B<sub>2</sub>‐Type Enzyme‐Responsive Amphiphiles for Drug Delivery
- Synthesis and transport potential study of <scp>A<sub>2</sub>B</scp> type double chain amphiphilic architectures
- Stimuli-responsive azo-functionalized non-ionic amphiphiles for controlled drug delivery applications
- Fabrication of hydrolase responsive diglycerol based Gemini amphiphiles for dermal drug delivery applications
Showing 5 of 6 shared publications
Rainer Haag
Freie Universität Berlin (DE)
6 shared publications
- Supramolecular Engineering of Alkylated, Fluorinated, and Mixed Amphiphiles
- Newer Non‐ionic A<sub>2</sub>B<sub>2</sub>‐Type Enzyme‐Responsive Amphiphiles for Drug Delivery
- Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures
- Fabrication of hydrolase responsive diglycerol based Gemini amphiphiles for dermal drug delivery applications
- Evaluation of Transport Potential of Alkylated and Fluoroalkylated Amphiphilic Hybrid Nanoarchitectures
Showing 5 of 6 shared publications
Katharina Achazi
Freie Universität Berlin (DE)
5 shared publications
- Newer Non‐ionic A<sub>2</sub>B<sub>2</sub>‐Type Enzyme‐Responsive Amphiphiles for Drug Delivery
- Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures
- Fabrication of hydrolase responsive diglycerol based Gemini amphiphiles for dermal drug delivery applications
- Evaluation of Transport Potential of Alkylated and Fluoroalkylated Amphiphilic Hybrid Nanoarchitectures
- Synthesis of <i>C</i><sub>3</sub>-symmetric star shaped amphiphiles for drug delivery applications
Badri Parshad
University of Delhi (IN)
4 shared publications
- Self-assembly of carbohydrate-based small amphiphiles and their applications in pathogen inhibition and drug delivery: a review
- Newer Non‐ionic A<sub>2</sub>B<sub>2</sub>‐Type Enzyme‐Responsive Amphiphiles for Drug Delivery
- Stimuli-responsive azo-functionalized non-ionic amphiphiles for controlled drug delivery applications
- Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures
Aarti Aarti
University of Delhi (IN)
4 shared publications
- Self-assembly of carbohydrate-based small amphiphiles and their applications in pathogen inhibition and drug delivery: a review
- Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants
- Synthesis and transport potential study of <scp>A<sub>2</sub>B</scp> type double chain amphiphilic architectures
- Synthesis of <i>C</i><sub>3</sub>-symmetric star shaped amphiphiles for drug delivery applications
Moh’d Khushman
Washington University in St. Louis (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
- 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors
Meredith S. Pelster
Sarah Cannon (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- A Randomized Phase II Trial of Gemcitabine, Nab-Paclitaxel, Cisplatin with or without a Medically Supervised Ketogenic Diet for Patients with Metastatic Pancreatic Cancer
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
Michael Cecchini
Yale Cancer Center (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
- 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors
Shivaani Kummar
Oregon Health & Science University (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
- 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors
Lalith Akella
AVEO Oncology (United States) (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
- 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors
Keith Orford
AVEO Oncology (United States) (US)
4 shared publications
- A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
- Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
- Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
- 2688MO A phase I/II trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor - Safety and preliminary antitumor activity in patients with desmoid tumors
Christoph Böttcher
Freie Universität Berlin (DE)
3 shared publications
- Supramolecular Engineering of Alkylated, Fluorinated, and Mixed Amphiphiles
- Newer Non‐ionic A<sub>2</sub>B<sub>2</sub>‐Type Enzyme‐Responsive Amphiphiles for Drug Delivery
- Study on the Self-Assembly and Dual-Stimuli-Responsive Behavior of Multi-amphiphilic Polymeric Architectures
Ayushi Mittal
University of Delhi (IN)
3 shared publications
- Self-assembly of carbohydrate-based small amphiphiles and their applications in pathogen inhibition and drug delivery: a review
- Fabrication of hydrolase responsive diglycerol based Gemini amphiphiles for dermal drug delivery applications
- Synthesis of <i>C</i><sub>3</sub>-symmetric star shaped amphiphiles for drug delivery applications
Antara Sharma
University of Delhi (IN)
3 shared publications
- Synthesis and transport potential study of <scp>A<sub>2</sub>B</scp> type double chain amphiphilic architectures
- Stimuli-responsive azo-functionalized non-ionic amphiphiles for controlled drug delivery applications
- Self‐Assembly and Transport Behaviour of Non‐ionic Fluorinated and Alkylated Amphiphiles for Drug Delivery
Saima Syeda
University of Delhi (IN)
3 shared publications
- Synthesis and transport potential study of <scp>A<sub>2</sub>B</scp> type double chain amphiphilic architectures
- Stimuli-responsive azo-functionalized non-ionic amphiphiles for controlled drug delivery applications
- Self‐Assembly and Transport Behaviour of Non‐ionic Fluorinated and Alkylated Amphiphiles for Drug Delivery
Similar Researchers
Based on overlapping research topics
Aram Parhizkar
University of Arkansas at Fayetteville
Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation
Hafsa Khan
University of Arkansas – Fort Smith
Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation
Anshel Bright
National Center for Toxicological Research
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation
Plant and animal studies
Yusra B. Medik
University of Arkansas for Medical Sciences
Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation
Wenbo Niu
University of Arkansas at Fayetteville
Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation
Brandon S.B. Canup
National Center for Toxicological Research
Drug Delivery Systems
Nanoparticle-Based Drug Delivery
Immune Response and Inflammation